Arcadia Biosciences heads into its May 15 earnings report as one of the more technically distressed micro-caps on Nasdaq, with the stock down nearly 50% year-to-date and trading at $1.07.
The price tells the clearest story here. RKDA has lost 19% in a single month and nearly half its value since January. The market cap is a hair over $2 million — a level that raises real questions about the company's capital position heading into the print. The RSI stands at a deeply oversold 34, suggesting sellers have been in control for some time without meaningful counter-rallies taking hold.
Short interest is not the driving force. At just 0.52% of the free float — a genuinely negligible level — there is no meaningful short position to speak of. Borrow availability is extraordinarily loose, at over 7,600% of short interest, meaning shares-to-borrow are essentially unconstrained. Cost to borrow has ticked up about 16% on the week to roughly 15.7% APR, and the ORTEX short score has eased slightly to 34.6, down from a recent high of 38 earlier in May. None of this points to short-seller conviction — the stock's weakness is being driven by something else entirely.
Past earnings reactions at RKDA have been uniformly negative. Three of the last four prints produced a negative five-day move, with losses ranging from 3.6% to nearly 30%. The March 2026 event was the worst of the recent run: the stock fell 13.5% on the day and shed another 7 percentage points over the following week. The sole positive reaction — a 5.3% day-one gain in November 2025 — reversed almost entirely within five sessions.
Analyst data is stale — the most recent coverage action from HC Wainwright dates to mid-2024 — and cannot be treated as a current signal. The only available institutional holders of note are index-tracking vehicles: Vanguard and State Street hold tiny passive positions, and no active manager appears in the top-10 holder list. That ownership structure means there is no strategic buyer providing a floor.
The print is therefore less a test of any particular financial metric and more a question of whether management can articulate a credible path through a prolonged operational and capital drawdown at a stock price that offers almost no margin for disappointment.
See the live data behind this article on ORTEX.
Open RKDA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
